Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

103.73 -0.50 (-0.48%)
Official Closing Price Updated: 7:00 PM EDT, Oct 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,296,267
Open 104.32
Bid (Size) 103.75 (8)
Ask (Size) 104.28 (1)
Prev. Close 104.23
Today's Range 103.70 - 105.11
52wk Range 99.80 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.82%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
A Look Into Merck & Co Inc's Price Over Earnings
Via Benzinga
Why Is Moderna Stock Trading Higher On Monday?
Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress in individualized cancer therapies. 
Via Benzinga

Performance

YTD
-8.40%
-8.40%
1 Month
-8.66%
-8.66%
3 Month
-10.00%
-10.00%
6 Month
-19.73%
-19.73%
1 Year
+1.02%
+1.02%

More News

Read More
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
What Lies In Store For Healthcare ETFs In Q3 Earnings?
Via Talk Markets
Topics ETFs
Where Will Merck Be in 5 Years?
Via The Motley Fool
(MRK) - Analyzing Merck & Co's Short Interest
Via Benzinga
Is NYSE:MRK a Good Fit for Dividend Investing?
Via Chartmill
Pfizer, Live Nation Entertainment And More On CNBC's 'Final Trades'
Via Benzinga
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
Via Benzinga
3 Absurdly Cheap Stocks That Pay High Dividends
Via The Motley Fool
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers
From Merck & Co., Inc.
Via Business Wire
CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older
From Merck & Co., Inc.
Via Business Wire
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
Via Benzinga
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
Via Talk Markets
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
Via Benzinga
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
From Gilead Sciences, Inc.
Via Business Wire
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
Via Benzinga
Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants
Via Benzinga
Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants
From Merck & Co., Inc.
Via Business Wire
Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease
From Merck & Co., Inc.
Via Business Wire
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
Via Investor's Business Daily
Exposures Product Safety
Up 700% This Year, Is It Too Late to Invest in This Stock?
Via The Motley Fool
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
Via MarketBeat
2 Incredibly Cheap Big Pharma Stocks to Buy Now
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.